Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 21 Sept 2018 |
| Genmab A/S has published its Articles of Association | 19 Sept 2018 |
| Genmab to Host Capital Markets Day | 19 Sept 2018 |
| Capital Increase in Genmab as a Result of Employee Warrant Exercise | 18 Sept 2018 |
| Genmab to Present at Morgan Stanley 16th Annual Global Healthcare Conference | 6 Sept 2018 |